CEPI/CfP2 – CEPI CfP2: Platform Technologies to enable rapid vaccine development for epidemic prone infections”

CV-NCOV-001 – A Phase 1, partially blind, placebo-controlled, dose-esclation, first-in-human, clinical trial to evaluate the safety, reactogenicity and immunogenicity after 1 and 2 doses of the investigational SARS-COV-2 mRNA vaccine CVnCoV administered intramuscularly in healthy adults